Corbus Pharmaceuticals Holdings Balance Sheet Health
Financial Health criteria checks 5/6
Corbus Pharmaceuticals Holdings has a total shareholder equity of $97.0M and total debt of $13.0M, which brings its debt-to-equity ratio to 13.4%. Its total assets and total liabilities are $125.7M and $28.8M respectively.
Key information
13.4%
Debt to equity ratio
US$12.95m
Debt
Interest coverage ratio | n/a |
Cash | US$120.10m |
Equity | US$96.97m |
Total liabilities | US$28.78m |
Total assets | US$125.74m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 3371's short term assets ($121.7M) exceed its short term liabilities ($25.9M).
Long Term Liabilities: 3371's short term assets ($121.7M) exceed its long term liabilities ($2.9M).
Debt to Equity History and Analysis
Debt Level: 3371 has more cash than its total debt.
Reducing Debt: 3371's debt to equity ratio has increased from 0.6% to 13.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 3371 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 3371 has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 0.1% each year.